“If successful in harnessing DNA instructions and a proprietary delivery platform to reprogram the immune system, Adimune has the potential to lead a new era of addressing diseases through programming ...

In the intricate regulation of inflammation, metabolic reprogramming and posttranslational modification (PTM) have emerged as pivotal players, offering new avenues for understanding the fine-tuned ...

Digestive tract tumors are malignant diseases characterized by high aggressiveness, heterogeneity and metabolic abnormalities. Heterogeneity and drug resistance among tumors pose a serious challenge ...

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...